Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles

被引:239
作者
Dreis, S.
Rothweller, F.
Michaelis, A.
Cinatl, J., Jr.
Kreuter, J.
Langer, K.
机构
[1] Univ Frankfurt, Inst Pharmaceut technol Bioctr Niederursel, D-60438 Frankfurt, Germany
[2] Univ Frankfurt, Univ Hosp Med Sch, Inst Med Virol, D-60596 Frankfurt, Germany
关键词
nanoparticles; doxorubicim; human serum albumin (HSA); physicochernical characterisation; cell viability;
D O I
10.1016/j.ijpharm.2007.03.036
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Human serum albumin (HSA) nanoparticles represent promising drug carrier systems. Binding of cytostatics to HSA nanoparticles may diminish their toxicity, optimise their body distribution and/or may overcome multidrug resistance. In the present study, doxorubicin-loaded HSA nanoparticle preparations were prepared. Doxorubicin was loaded to the HSA nanoparticles either by adsorption to the nanoparticles' surfaces or by incorporation into the particle matrix. Both loading strategies resulted in HSA nanoparticles of a size range between 150 nm and 500 nm with a loading efficiency of 70-95%. The influence on cell viability of the resulting nanoparticles was investigated in two different neuroblastoma cell lines. The anti-cancer effects of the drug-loaded nanoparticles were increased in comparison to doxorubicin solution. Based on these result a standard protocol for the preparation of doxorubicin-loaded HSA nanoparticles for further antitumoural studies was established. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:207 / 214
页数:8
相关论文
共 35 条
[1]
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats [J].
Ambruosi, A ;
Khalansky, AS ;
Yamamoto, H ;
Gelperina, SE ;
Begley, DJ ;
Kreuter, J .
JOURNAL OF DRUG TARGETING, 2006, 14 (02) :97-105
[2]
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo [J].
Barraud, L ;
Merle, P ;
Soma, E ;
Lefrançois, L ;
Guerret, S ;
Chevallier, M ;
Dubernet, C ;
Couvreur, P ;
Trépo, C ;
Vitvitski, L .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :736-743
[3]
CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
[4]
APHIDICOLIN SELECTIVELY KILLS NEUROBLASTOMA-CELLS INVITRO [J].
CINATL, J ;
CINATL, J ;
MAINKE, M ;
WEISSFLOG, A ;
STEIGMANN, G ;
RABENAU, H ;
DOERR, HW ;
KORNHUBER, B .
CANCER LETTERS, 1992, 67 (2-3) :199-206
[5]
HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates [J].
Configliacchi, E ;
Razzano, G ;
Rizzo, V ;
Vigevani, A .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 15 (01) :123-129
[6]
DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE [J].
CUVIER, C ;
ROBLOTTREUPEL, L ;
MILLOT, JM ;
LIZARD, G ;
CHEVILLARD, S ;
MANFAIT, M ;
COUVREUR, P ;
POUPON, MF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) :509-517
[7]
Damascelli B, 2001, CANCER, V92, P2592, DOI 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO
[8]
2-4
[9]
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer [J].
Duncan, R ;
Vicent, MJ ;
Greco, F ;
Nicholson, RI .
ENDOCRINE-RELATED CANCER, 2005, 12 :S189-S199
[10]
The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360